Table 1. Characteristics of the Studied Population Stratified by SARS-CoV-2 Development.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Total population of patients receiving active antitumor treatment (January 15-May 4, 2020) |
Patients developing SARS-CoV-2 infection | Patients not developing SARS-CoV-2 infection | |
| No. | 59 989 | 406 (0.68) | 59 583 (99.32) |
| Age, median (range), y | 65 (20-97) | 68 (28-89) | 65 |
| Female | 31 876 (53.2) | 184 (45.3) | 31 692 (53.2) |
| Male | 25 878 (43.1) | 219 (53.9) | 25 659 (43.1) |
| Unknown | 2235 (3.7) | 3 (0.7) | 2232 (3.7) |
| Cancer type | |||
| Lung | 5460 (9.1) | 91 (22.4) | 5369 (9) |
| Breast | 10 321 (17.2) | 75 (18.5) | 10 246 (17.2) |
| Colorectal | 6141 (10.2) | 38 (9.4) | 6103 (10.3) |
| Prostate | 2735 (4.6) | 35 (8.6) | 2700 (4.5) |
| Other | 12 826 (21.4) | 164 (40.4) | 12 662 (21.3) |
| Gynecologic | NS | 19 (4.7) | NS |
| Urothelial | NS | 15 (3.7) | NS |
| Hematologic | NS | 24 (5.9) | NS |
| Upper GI (gastric, biliary, pancreatic) | NS | 42 (10.3) | NS |
| Melanoma and skin | NS | 11 (2.7) | NS |
| Kidney | NS | 9 (2.2) | NS |
| Soft tissue sarcoma | NS | 17 (4.2) | NS |
| Others types of tumor | NS | 27 (6.7) | NS |
| Unknown | 22 506 (37.5) | 3 (0.7) | 22 503 (37.5) |
| Antineoplastic therapy | |||
| Chemotherapy +/– biologics | 20 895 (34.8) | 244 (60.1) | 20 651 (34.7) |
| Chemo-immunotherapy | 1099 (1.8) | 8 (2) | 1091 (1.8) |
| Immunotherapy | 4327 (7.2) | 41 (10.1) | 4286 (7.2) |
| Targeted | 5974 (10) | 74 (18.2) | 5900 (9.9) |
| Others | 3881 (6.5) | 36 (8.9) | 3845 (6) |
| Hormone | NA | 34 (8.4) | NA |
| Other types of treatment | NA | 2 (0.5) | NA |
| Unknown | 23 813 (39.7) | 3 (0.7) | 23 810 (40) |
| Clinical presentation | |||
| Symptomatic | NA | 339 (83.4) | NA |
| Asymptomatic (contact with a known positive case) | NA | 63 (15.6) | NA |
| Unknown | NA | 4 (1) | NA |
| Hospitalization | |||
| Yes | NA | 314 (77.3) | NA |
| No | NA | 87 (21.4) | NA |
| Unknown | NA | 5 (1.2) | NA |
Abbreviations: NA, not applicable; NS, not specified; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.